Mitochondrial DNA genotyping efficiently reveals clonality of synchronous endometrial and ovarian cancers

Modern Pathology

Volumn 27, Issue 10, 2014, Pages 1412-1420

  Guerra, Flora ^a   Girolimetti, Giulia ^a   Perrone, Anna Myriam ^a   Procaccini, Martina ^a   Kurelac, Ivana ^a   Ceccarelli, Claudio ^b   De Biase, Dario ^c   Caprara, Giacomo ^a   Zamagni, Claudio ^a   De Iaco, Pierandrea ^a   Santini, Donatella ^a   Gasparre, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c BELLARIA HOSPITAL   (Italy)

Author keywords

Gynecological cancer; Mitochondrial DNA mutations; Synchronous tumors

Indexed keywords

BETA CATENIN; MITOCHONDRIAL DNA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CLONAL VARIATION; CTNNB1 GENE; DNA DETERMINATION; DNA SEQUENCE; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MICROSATELLITE INSTABILITY; MIDDLE AGED; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; DIFFERENTIAL DIAGNOSIS; ENDOMETRIAL NEOPLASMS; GENETICS; GENOTYPING TECHNIQUE; NEOPLASM METASTASIS; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS;

ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; DNA, MITOCHONDRIAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENOTYPING TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS;

EID: 84925271613     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.39     Document Type: Article

References (24)

1. Ulbright TM, Roth LM. Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol 1985;16:28-34.
2. Scully RE YR, Clement PB. Atlas of Tumor Pathology: Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube and Broad Ligament 1998;27-50.
3. Singh N. Synchronous tumours of the female genital tract. Histopathology 2010;56:277-285.
4. Bookman MA. First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol 2012;55:96-113.
5. Hill EK, Dizon DS. Medical therapy of endometrial cancer: current status and promising novel treatments. Drugs 2012;72:705-713.
6. Guerra F, Kurelac I, Magini P, et al. Mitochondrial DNA genotyping reveals synchronous nature of simultaneously detected endometrial and ovarian cancers. Gynecol Oncol 2011;122:457-458.
7. Brandon M, Baldi P, Wallace DC. Mitochondrial mutations in cancer. Oncogene 2006;25:4647-4662.
8. Guerra F, Kurelac I, Cormio A, et al. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet 2011;20:2394-2405.
9. Foschini MP, Morandi L, Marchetti C, et al. Cancerization of cutaneous flap reconstruction for oral squamous cell carcinoma: report of three cases studied with the mtDNA D-loop sequence analysis. Histopathology 2011;58:361-367.
10. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-892.
11. Sobin LH, Wittekind Ch (eds). UICC (International Union Against Cancer). TNM classification of malignant tumours, 6th ed. Wiley-Liss: New York, Chichester, Weinheim, Brisbane, Singapore, Toronto, 2002.
12. Morandi L, de Biase D, Visani M, et al. T([20]) repeat in the 3′-untranslated region of the MT1X gene: a marker with high sensitivity and specificity to detect microsatellite instability in colorectal cancer. Int J Colorectal Dis 2012;27:647-656.
13. Kurelac I, MacKay A, Lambros MB, et al. Somatic complex I disruptive mitochondrial DNA mutations are modifiers of tumorigenesis that correlate with low genomic instability in pituitary adenomas. Hum Mol Genet 2013;22:226-238.
14. Porcelli AM, Ghelli A, Ceccarelli C, et al. The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum Mol Genet 2010;19:1019-1032.
15. Kurelac I, Lang M, Zuntini R, et al. Searching for a needle in the haystack: comparing six methods to evaluate heteroplasmy in difficult sequence context. Biotechnol Adv 2012;30:363-371.
16. Frueh FW, Noyer-Weidner M. The use of denaturing high-performance liquid chromatography (DHPLC) for the analysis of genetic variations: impact for diagnostics and pharmacogenetics. Clin Chem Lab Med 2003;41:452-461.
17. Irving JA, Catasus L, Gallardo A, et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 2005;36:605-619.
18. Silva R, Marie SK, Uno M, et al. CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants. Clinics 2013;68:167-172.
19. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-4791.
20. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151-160.
21. Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol 2005;205:130-144.
22. Chang KH, Albarracin C, Luthra R, et al. Discordant genetic changes in ovarian and endometrial endometrioid carcinomas: a potential pitfall in molecular diagnosis. Int J Gynecol Cancer 2006;16:178-182.
23. Rubino F, Piredda R, Calabrese FM, et al. HmtDB, a genomic resource for mitochondrion-based human variability studies. Nucleic Acids Res 2012;40: Database issue D1150-D1159.
24. Iommarini L, Calvaruso MA, Kurelac I, Gasparre G, Porcelli AM. Complex I impairment in mitochondrial diseases and cancer: parallel roads leading to different outcomes. Int J Biochem Cell Biol 2012;45:47-63.